Shilpa Medicare Q3 results.
Financial Highlights (consolidated)
Congratulations to the management team and we minority shareholders for the USFDA approval (API sites) and a good set of quarterly numbers.
Hi,
What I would like to know will there be any adverse impact on Shilpa or Natco for this new rule made by govt to withdraw exemption in import.
Any impact or disruption for Shilpa Medicare’s business?
http://timesofindia.indiatimes.com/home/science/Briton-among-first-patients-to-be-injected-with-cancer-vaccine/articleshow/51232786.cms
Another news on similar line ~ http://health.economictimes.indiatimes.com/news/industry/scientists-discover-achilles-heel-of-cancer/51264269.
Though all these developments are at a very initial stage (at least 3~4 years away of commercial virtue), disruption in traditional cancer treatment is imminent. We, as a shareholder hope Shilpa gets USFDA approval of formulation unit early enough and the company delivers on its potential.
We would need to see how the vaccine succeeds (personally, would wish it succeeds). It is in trial stage; to run over the next two years involving up to 30 volunteers. At end of the day it has to be effective, safe, versatile and commercially viable. Will have to wait and see.
As Hiteshbhai says “There is a huge deluge of newsflows on almost all companies and one needs to prioritize what is important and what is not” (for now).
Till then, let’s enjoy the joker in the pack (USFDA approval). The single biggest risk factor is behind us. Cheers.
depending heavily on just one branch of medecine is always a risk for any pharma co , would prefer to be in businesses that are diversified across major verticals.immunotherapy is making steady progress in the fight against cancer but is yet to be commercialised.
Shilpa Medicare Ltd has informed BSE that the Company received GMP compliance certificate for two API sites (Unit-1: Deosugur Industrial Area, Deosugur-584170, Raichur, Karnataka, India; Unit-2: Plot nos. 33, 33A, 40 to 47, Raichur Industrial growth Centre, Wadloor Road, Chicksugur-584134, Raichur, Karnataka, India) from PMDA-Japan.
http://www.bseindia.com/corporates/ann.aspx?scrip=530549&dur=A&expandable=0
Is it possible to get any guesstimate on revenue from current flurry of FDA approvals?
The March quarter ending DMF filing list with USFDA is out and Shilpa has filed two DMFs (including one filed in December which got recorded in this quarter’s filing) taking its total tally of DMF filed to 26 now. The details are given below:
Shilpa Q4 and FY16 numbers are out and predictably very good.
Disc: Invested
In terms of ROE or its expansion it is not very good and negative on incremental return by way of profits. I am perplexed what could be the reason for this. Is it a red flag. Natco is far ahead in this measure.
Shilpa Medicare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on June 27, 2016, inter alia, to consider a proposal of merger of Navya Boilogicals Private Limited with the Company.
Navya Biologicals Private Limited (“NBPL”) is a company incorporated under the Companies Act, is engaged on research and development activities in the field of biologicals. NBPL has specifically been in the development of bio-similars and product process technologies.
Arrow Greentech has filed a suit on Shilpa / Nu Therapeutics
Promoters have increased their stake by 3.84% @BSE latest share holding pattern. http://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=530549&qtrid=90.00
That looks like increase by way of gifts within family. Sr. members gifting to new generation.
Successful USFDA audit completed for formulations facility at Jadcherla.
http://www.bseindia.com/corporates/anndet_new.aspx?newsid=3fc8871a-6921-45be-8e39-8007d45d00dd
10% YoY type growth reported in Q1FY17. Normally, the first quarter is soft for Shilpa.
